

Third Quarter 2020 Update

Dear Friend of Navigation Sciences,

We are pleased to report on the financial and development progress Navigation Sciences has made over the past several months. The Series 'A' financing, which was over-subscribed, is now closed. We raised nearly \$2.4 million for the round. The funding is a strong vote of confidence in the progress we have made to date and in the potential of our NaviSci™ technology to transform surgery for lung cancer and other soft tissue tumors.

These funds will allow us to complete the company's upcoming, first-in-man clinical trial and achieve its next critical milestones. These include the demonstration of the system's potential to localize and remove lung tumors with sufficient margins in real-time, sparing tissue to preserve lung function, and improving the surgical workflow. We are working with the Brigham and Women's Hospital Institutional Review Board (IRB) on final details to secure approval of the clinical trial and the study remains on a trajectory to begin before the end of the year.

The first patent filed by Navigation Sciences independent of Brigham and Women's Hospital also advanced. We converted the provisional submission into a PCT patent application (International Patent System), which we expect will result in multiple patents over time.

Finally, we gained additional recognition through participation in UMass Lowell's annual Massachusetts Medical Device Development Center (M2D2) \$200K Challenge. Navigation Sciences was a finalist out of over 200 applicants and received three, in-kind service awards from the program's sponsors.

I hope you and your family stay safe. As always, thank you for your support.

Sincerely,

Alan D. Lucas

CEO